New hope for leukemia patients: targeted drug combo after transplant

NCT ID NCT07463651

First seen Mar 17, 2026 · Last updated May 13, 2026 · Updated 9 times

Summary

This study is for people with a specific genetic form of acute myeloid leukemia (FLT3-ITD) who have had a stem cell transplant. It compares two drugs, gilteritinib and sorafenib, given as maintenance therapy to prevent the cancer from coming back. About 594 participants will be randomly assigned to one of the two drugs and monitored for two years. The goal is to see which drug better keeps the disease in remission and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • the First Affiliated Hosptital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.